
    
      This is a phase III, randomized, controlled, open, multicenter clinical trial, designed to
      assess the efficacy and safety of prophylactic cranial irradiation (PCI) in advanced triple
      negative breast cancer who response to the first line chemotherapy. Compare the PCI group
      with the observation group to evaluate brain metastasis-free survival,cumulative risk of
      brain metastases within 1 year,progression-free survival,overall survival,quality of life
      measured by the The Europe organization for research and treatment of cancer, Quality of life
      Questionnaire-cancer 30 (EORTC-QLQ-C30) questionnaire score and function of central nervous
      measured by the The Europe organization for research and treatment of cancer, Quality of life
      Questionnaire-brain cancer 20 (EORTC-QLQ-BN20) questionnaire score in women with advanced
      triple negative breast cancer who response to the first line chemotherapy.
    
  